Is there any data/questionnaires that would make CYDY think that HIV patients WOULDN’T use a less toxic, once a week injectable over a daily regime with worse side effects? I understand the aversion to needles, but the reduction or elimination of side effects would out weigh it for me. I think it’s an interesting point but I doubt CYDY would spend $200 million getting leronlimab approved if they thought only a small percentage of HIV patients would use an injectable drug.